RT Journal Article
T1 Metabolically Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC).
A1 Kliemann, Nathalie
A1 Ould Ammar, Romain
A1 Biessy, Carine
A1 Gicquiau, Audrey
A1 Katzke, Verena
A1 Kaaks, Rudolf
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Sanchez-Perez, Maria-Jose
A1 Crous-Bou, Marta
A1 Pasanisi, Fabrizio
A1 Tin Tin, Sandar
A1 Perez-Cornago, Aurora
A1 Aune, Dagfinn
A1 Christakoudi, Sofia
A1 Heath, Alicia K
A1 Colorado-Yohar, Sandra M
A1 Grioni, Sara
A1 Skeie, Guri
A1 Sartor, Hanna
A1 Idahl, Annika
A1 Rylander, Charlotta
A1 May, Anne M
A1 Weiderpass, Elisabete
A1 Freisling, Heinz
A1 Playdon, Mary C
A1 Rinaldi, Sabina
A1 Murphy, Neil
A1 Huybrechts, Inge
A1 Dossus, Laure
A1 Gunter, Marc J
AB Obesity is a risk factor for endometrial cancer but whether metabolic dysfunction is associated with endometrial cancer independent of body size is not known. The association of metabolically defined body size phenotypes with endometrial cancer risk was investigated in a nested case-control study (817 cases/ 817 controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of C-peptide were used to define metabolically healthy (MH;  In a multivariable-adjusted conditional logistic regression model, compared with MH/NW individuals, endometrial cancer risk was higher among those classified as MU/NW [ORWC, 1.48; 95% confidence interval (CI), 1.05-2.10 and ORWHR, 1.68; 95% CI, 1.21-2.35] and MU/OW (ORBMI, 2.38; 95% CI, 1.73-3.27; ORWC, 2.69; 95% CI, 1.92-3.77 and ORWHR, 1.83; 95% CI, 1.32-2.54). MH/OW individuals were also at increased endometrial cancer risk compared with MH/NW individuals (ORWC, 1.94; 95% CI, 1.24-3.04). Women with metabolic dysfunction appear to have higher risk of endometrial cancer regardless of their body size. However, OW status raises endometrial cancer risk even among women with lower insulin levels, suggesting that obesity-related pathways are relevant for the development of this cancer beyond insulin. Classifying women by metabolic health may be of greater utility in identifying those at higher risk for endometrial cancer than anthropometry per se.
PB American Association for Cancer Researc
YR 2022
FD 2022-04-13
LK http://hdl.handle.net/10668/20184
UL http://hdl.handle.net/10668/20184
LA en
NO Kliemann N, Ould Ammar R, Biessy C, Gicquiau A, Katzke V, Kaaks R, et al. Metabolically Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1359-1367.
NO The coordination of EPIC is financially supported by International Agencyfor Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London that hasadditional infrastructure support provided by the NIHR Imperial BiomedicalResearch Center (BRC). The national cohorts are supported by: Danish CancerSociety (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, MutuelleG en erale de l’Education Nationale, Institut National de la Sant e et de laRecherche M edicale (INSERM; France); German Cancer Aid, German CancerResearch Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF; Germany);Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia diSanPaolo and National Research Council (Italy); Dutch Ministry of PublicHealth, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LKResearch Funds, Dutch Prevention Funds, Dutch ZON (Zorg OnderzoekNederland), World Cancer Research Fund (WCRF—ERC-2009-AdG 232997),Statistics Netherlands (the Netherlands); Health Research Fund (FIS)—Institutode Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias,Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and CountyCouncils of Ska ne and V€asterbotten (Sweden); Cancer Research UK (14136 toEPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council(1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford, United Kingdom).This work was supported by a grant from Cancer Research UK (C19335/A21351; to M.J. Gunter).
DS RISalud
RD Apr 6, 2025